1. Glossary of Common Terms. NIH Clinical Research Trials and You. Available at: Glossary of Common Terms | National Institutes of Health (NIH). Accessed Nov 2024.

2. Glossary Terms. ClinicalTrials.gov. Available at: ClinicalTrials.gov Glossary Terms | ClinicalTrials.gov. Accessed Nov 2024.

3. Juif PE, Ufer M, Dingemanse J. Cardiodynamic Interactions between Two S1P1 Receptor Modulators in an Experimental Clinical Setting: Different Pharmacokinetic Properties as an Opportunity to Mitigate First-Dose Heart Rate Effects. Int J Mol Sci. 2019 Jul ;20(13):32320.

4. Juif PE, Baldoni D, Reyes M, Wilbraham D, Febbraro S, Vaclavkova A, Hoch M, Dingemanse J. Pharmacokinetics, Pharmacodynamics, Tolerability, and Food Effect of Cenerimod, a Selective S1P₁ Receptor Modulator in Healthy Subjects. Int J Mol Sci. 2017 Dec 6;18(12):2636.

5. Boof ML, van Lier JJ, English S, Fischer H, Ufer M, Dingemanse J. Absorption, distribution, metabolism, and excretion of cenerimod, a selective S1P1 receptor modulator in healthy subjects. Xenobiotica. 2020 Aug;50(8):947-956.

6. Juif PE, Dingemanse J, Winkle P, Ufer M. Pharmacokinetics and Pharmacodynamics of Cenerimod, A Selective S1P1 R Modulator, Are Not Affected by Ethnicity in Healthy Asian and White Subjects. Clin Transl Sci. 2021 Jan;14(1):143-147.

7. Juif PE, Mueller MS, Charfi H, Dingemanse J. Lack of Effect of Cenerimod, a Selective S1P1 Receptor Modulator, on the Pharmacokinetics of a Combined Oral Contraceptive. Int J Mol Sci. 2022 Nov 29;23(23):14986.

8. Hermann V, Batalov A, Smakotina S, Juif PE, Cornelisse P. First use of cenerimod, a selective S1P1 receptor modulator, for the treatment of SLE: a double-blind, randomised, placebo-controlled, proof-of-concept study. Lupus Sci Med. 2019 Nov 9;6(1):e000354.

9. Askanase A, Berkani O, Cahuzac c, Cornelisse p, D’Cruz D, Kalunian K, Merrill J, Pozzobon M, Navarra S. Efficacy and Safety of Cenerimod in Patients with Moderate to Severe Systemic Lupus Erythematosus (SLE): A Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled, Dose-Finding Phase 2b Trial [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9): 3293–3297.

10. Hoyler TF, Strasser DS, Berkani O, et al. LO-016 The multifaceted immunomodulatory properties of cenerimod, a selective S1P1 receptor modulator, target three key aspects of SLE pathogenesis. Lupus Sci Med. 2023;10.

11. Gerossier E, Nayar S, Froidevaux S, et al. Cenerimod, a selective S1P1 receptor modulator, improves organ-specific disease outcomes in animal models of Sjögren’s syndrome. Arthritis Res Ther. 2021;23(1):289.

12. The basics. NIH Clinical Research Trials and You. Available at: The Basics|National Institutes of Health (NIH). Accessed Nov 2024.

13. What is an investigational new drug. NIH. . Available at: https://www.niaid.nih.gov/grants-contracts/investigational-new-drug-definition. Accessed Nov 2024.